




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6






FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 29

FIG. 28




FIG. 30




FIG. 31




FIG. 32

30/137




FIG. 33




FIG. 34




FIG. 35




FIG. 36

32/137




FIG. 37




FIG. 38

34/137




FIG. 39

FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45




FIG. 46




FIG. 47




FIG. 49




FIG. 50




FIG. 48




FIG. 51

FIG. 52




FIG. 53




FIG. 55




FIG. 54




FIG. 56




FIG. 57




FIG. 58




FIG. 59




FIG. 60




FIG. 61




FIG. 62




FIG. 63




FIG. 64




FIG. 65




FIG. 66




FIG. 67




FIG. 68A




FIG. 68B




FIG. 69




FIG. 70





FIG. 71






FIG. 72B




FIG. 73




FIG. 74

4800




FIG. 75




FIG. 76





FIG. 77



5100





FIG. 79



To FIG 80B

FIG. 80A




FIG. 80B




FIG. 81




FIG. 82A




FIG. 82B




FIG. 83




FIG. 84




FIG. 85




FIG. 86




FIG. 87




FIG. 88





FIG. 89



Note 1: The supply voltage (Vs) to the Devices could be programmed or a constant

FIG. 90




FIG. 91




FIG. 92




FIG. 93




FIG. 94




FIG. 95




FIG. 96




FIG. 97




FIG. 98




FIG. 99




FIG. 100




FIG. 101

7200




FIG. 102




FIG. 103




FIG. 104




FIG. 105




FIG. 106




FIG. 107




FIG. 108




FIG. 109




FIG. 110




FIG. 111





FIG. 112




FIG. 113




FIG. 114




FIG. 115




FIG. 116




FIG. 117



FIG. 118




FIG. 119




FIG. 120




FIG. 121




FIG. 122




FIG. 123




FIG. 124

12500




FIG. 125




FIG. 126




FIG. 127




FIG. 128




FIG. 129




FIG. 130




FIG. 131

PT List	IV List
McKnight, James	01-Apr-1960
MRN: 23478654	M 2 days
2 East/2145	75 kg

Pump Pod 1	Pump Pod 2	Micro Pump 1
Channel A	Channel A	Insulin
Nitroglycerin	Clarithromycin	U100
5 mg/kg/min	500 mg	5 units/hour
3mL/hour	IVSS Q12H	
Channel B		
Abciximab		
0.125 mcg/kg/min		
5.25 mL/hour		

PT Dash	PT Info	Worklist	IV List
---------	---------	----------	---------

FIG. 134

Occlusion Checklist

- ☐ Inspect infusion site
- ☐ Inspect the catheter
- ☐ Inspect the entire IV line for kinks or other obstructions
- ☐ Inspect for any visible obstructions in the IV tubing

Check for occlusion?

FIG. 133

5 R's Confirmed

- ☐ Right Patient
- ☐ Right Route
- ☐ Right Dose
- ☐ Right Time
- ☐ Right Medicine

FIG. 132

2:51 PM

☒ Patient List General Hospital

	Adams, M 72/M Account: A0015077 Pneumonia	26
	Arterburn, A 60/F Account: A0001875 Acute Coronary Syndrome	27
	Holcomb, V 45/F Account: H00858183 Acute Renal Failure	
	Ignatoski, M 36/M Account: I00058533 Diverticulitis	
	★ Jones, A	

11

FIG. 135




FIG. 136

2:51 PM

Arterburn, A Room 308

60/F Account: A0001875
Acute Coronary Syndrome

Intravenous Pump
System In stand-by...

Nitroglycerin: IV PDR

Usual range: 5-10 mcg/minute

5-10 mcg/minute dose

NS type 100 cc/hr fluid rate

Submit Prescription

11

28

29

30

31

FIG. 137

2:51 PM

☒ Arterburn, A Room 308

WARNING:

Medication Database

Nitroglycerin and Zanaflex

(1 of 2) Clinically Significant Adverse
table: hypotension, liver injury and seda-
tion...

(2 of 2) Additive hypotensive effect:
Zanaflex (tizanidine) 4mg, four times a day

RECOMMENDATION

Decrease rate 50% from mcg/minute to:

Change to 2.5 mcg/minute PDR

Manually adjust dose

Add note

11

32

33

5

FIG. 138

2:51 PM

Arterburn, A Room 308

60/F Account: A0001875
Acute Coronary Syndrome

Intravenous Pump
System In stand-by...

Nitroglycerin: IV PDR

Usual range: 5-10 mcg/minute

2.5 mcg/minute dose

NS type 100 cc/hr fluid rate

Submit Prescription

Corrective Actions

CAR-040539 Jan. 22, 2012 14:51

Nitroglycerin and Zanaflex

11

33

34

FIG. 139




FIG. 140




FIG. 141




FIG. 142




FIG. 143

123/137




FIG. 144




FIG. 145




FIG. 146




FIG. 147




FIG. 148




FIG. 149




FIG. 151




FIG. 152

132/137



Fig. 153A

133/137


2001
Cont.

Fig. 153B

134/137




Fig. 154

135/137




Fig. 155

136/137




Fig. 156

137/137





Fig. 157






FIG. 2

+




FIG. 4

+




FIG. 6

+




FIG. 7

+

+




FIG. 8

+

+




FIG. 9

+

+




FIG. 10

+

+




FIG. 11

+

+




FIG. 12

+




FIG. 13

+




FIG. 14

+

+




FIG. 15

+




FIG. 16




FIG. 17

+




FIG. 18

+




FIG. 19

+




FIG. 20

+

+




FIG. 21

+

+




FIG. 22

+

+




FIG. 23

+




FIG. 24

+




FIG. 25

+

+




FIG. 26

+

+




FIG. 27

+

+




FIG. 29




FIG. 28

+

+




FIG. 30




FIG. 31




FIG. 32

+

+




FIG. 33




FIG. 34




FIG. 35

+

+




FIG. 36

+

+




FIG. 37

+

+




FIG. 38

+

+




FIG. 39

FIG. 40

+

+




FIG. 41

+

+




FIG. 42




FIG. 43

+

+




FIG. 44

+

+




FIG. 45

+

+




FIG. 46

+

+




FIG. 47

+

+




FIG. 49




FIG. 50




FIG. 48

+

+




FIG. 52




FIG. 51

+

+




FIG. 53

+

+




FIG. 55




FIG. 54

+

+




FIG. 57




FIG. 58




FIG. 56

+




FIG. 59

+




FIG. 60

+

+




FIG. 61

+

+




FIG. 62

+

+




FIG. 63

+

+




FIG. 64

+

+




FIG. 65

+




FIG. 66

+




FIG. 67

+

+




FIG. 68A

+

+




FIG. 68B

+

+




FIG. 69




FIG. 70

+

+




FIG. 71

+

+




FIG. 72A

+

+




FIG. 72B

+

+




FIG. 73

+

+




FIG. 74

+

+




FIG. 75

+

+




FIG. 76

+

+




FIG. 77

+

+




FIG. 78

+

+




FIG. 79

+

+




FIG. 80A

+

+




FIG. 80B

+

+




FIG. 81

+

+




FIG. 82A

+

+




FIG. 82B

+

+




FIG. 83




FIG. 84

+

+




FIG. 85

+

+




FIG. 86

+

+




FIG. 87

+

+




FIG. 88

+

+





FIG. 89

+



Note 1: The supply voltage (V_s) to the Devices could be programmed or a constant

FIG. 90




FIG. 91

+




FIG. 92

+



FIG. 93




FIG. 94

+




FIG. 95




FIG. 96

+

+




FIG. 97




FIG. 98

+




FIG. 99

+




FIG. 100

+

+




FIG. 101

+

+

7200




FIG. 102

+




FIG. 103

+




FIG. 104

+

+




FIG. 105

+

+




FIG. 106

+




FIG. 107

+




FIG. 108

+

+




FIG. 109

+

+




FIG. 110

+

+




FIG. 111




FIG. 112




FIG. 113




FIG. 114

+

+




FIG. 115




FIG. 116

+

+




FIG. 117




FIG. 118

+

+




FIG. 119

+

+




FIG. 120

+

+




FIG. 121




FIG. 122

+




FIG. 123

+




FIG. 124

+

+

12500




FIG. 125

+

+




FIG. 126

+

+




FIG. 127

+

+




FIG. 128

+

+




FIG. 129

+

+




FIG. 130

+

+




FIG. 131

+

PT List	IV List
McKnight, James	01-Apr-1960
MRN: 23478654	M 2 days
2 East/2145	75 kg

Pump Pod 1

Channel A ☒

Nitroglycerin

5 mcg/kg/min

3mL/hour

Channel B ☒

Abciximab

0.125 mcg/kg/min

5.25 mL/hour

Pump Pod 2

Channel A ☒

Clarithromycin

500 mg

IVSS Q12H

Micro Pump 1 ☒

Insulin

U100

5 units/hour

³⁷

PT Dash

PT Info

⁴² Worklist

IV List

FIG. 134

Occlusion Checklist

☐ Inspect infusion site

☐ Inspect the catheter

☐ Inspect the entire IV line for kinks or other obstructions

☐ Inspect for any visible obstructions in the IV tubing

Check for occlusion?

☒ Silence

Home

☒ Yes

FIG. 133

5 R's Confirmed

☐ Right Patient

☐ Right Route

☐ Right Dose

☐ Right Time

☐ Right Medicine

☒ Cancel

Next

FIG. 132

+

2:51 PM

 Patient List

General Hospital

	<div>Adams, M</div> <div>72/M Account: A0015077</div> <div>Pneumonia</div>	<div>26</div> <div>27</div>
	<div> Arterburn, A</div> <div>60/F Account: A0001875</div> <div>Acute Coronary Syndrome</div>	
	<div>Holcomb, V</div> <div>45/F Account: H00858183</div> <div>Acute Renal Failure</div>	
	<div>Ignatoski, M</div> <div>36/M Account: I00058533</div> <div>Diverticulitis</div>	
	<div>★</div> <div>Jones, A</div>	

11

FIG. 135

+

+




FIG. 136

+

+

2:51 PM

Arterburn, ARoom 308



!

60/F Account: A0001875
Acute Coronary Syndrome



↔

⏱⏰🔒⚠

Intravenous Pump
System In stand-by...

Nitroglycerin: IV

PDR

Usual range: 5-10 mcg/minute

5-10

mcg/minute

dose

NS

type

100

cc/hr

fluid rate

Submit Prescription

11

30

28

29

31

FIG. 137

+

+

2:51 PM

Arterburn, A

Room 308

WARNING:

Medication Database

Nitroglycerin and Zanaflex

(1 of 2) Clinically Significant Adverse table: hypotension, liver injury and sedation...

(2 of 2) Additive hypotensive effect: Zanaflex (tizanidine) 4mg, four times a day

RECOMMENDATION

Decrease rate 50% from mcg/minute to:

Change to 2.5 mcg/minute

PDR

Manually adjust dose

Add note

32

5

33

11

FIG. 138

+

+

2:51 PM

Arterburn, A Room 308




60/F Account: A0001875
Acute Coronary Syndrome




Intravenous Pump
System In stand-by...

Nitroglycerin: IV

PDR

Usual range: 5-10 mcg/minute

2.5

mcg/minute

dose

NS

type

100

cc/hr

fluid rate

Submit Prescription

Corrective Actions

CAR-040539 Jan. 22, 2012 14:51

Nitroglycerin and Zanaflex

11

33

34

FIG. 139

+

+




FIG. 140

+

+




FIG. 141

+

+




FIG. 142

+

+




FIG. 143

+

+




FIG. 144

+

+




FIG. 145

+

+




FIG. 146

+

+




FIG. 147

+

+




FIG. 148

+




FIG. 149

+




FIG. 150

+

+




FIG. 151

+

+




FIG. 152

+




Fig. 153A




Fig. 153B




Fig. 154




Fig. 155




Fig. 156




Fig. 157




Fig. 158

21040




Fig. 159

Physiological variable	Sensor	Example medical condition
Heart activity	Electrocardiogram (EKG)	Heart attack
Body Temperature	Thermometer	Fever
Regional temperature	Thermometer	Diabetes
Blood-O ₂ saturation	Pulse oximetry	Heart attack
Pulse	Plethysmograph	Heart attack
Blood pressure	Sphygmomanometer	Hypertension
Heart rate	Heart rate monitor	Heart attack
Blood glucose	Blood glucose meter	Diabetes
Respiration rate	Costal expansion meter	Chronic obstructive pulmonary disease
Galvanic skin response	Ohmeter	Stress
Skin surface temperature	Thermometer	Fever
Ventricular pressure	Pressure transducer	Aortic stenosis
Muscle activity	Electromyography (EMG)	Seizure
Brain activity	Electroencephalogram (EEG)	Seizure
Body position	Accelerometer	Pressure ulcers
Heart image	Echocardiogram, cardiac computerized tomography, magnetic resonance imaging	Heart attack
Artery diameter	Angiogram	Atherosclerosis
Blood chemistry	Serum assay	
Creatine kinase		Heart attack
Lactate dehydrogenase		Heart attack
Cortisol levels		Stress
Troponin		Heart attack
Aspartate aminotransferase		Liver disease
myoglobin		Muscle damage
Ischemia modified albumin		Ischemia
Brain natriuretic peptide		Heart failure
Glycogen phosphorylase isoenzyme		Acute coronary syndrome
Acid-base balance	pH meter	Gastroesophageal reflux
Functional lung volume	Spirometer	Asthma

Fig. 160


Sensor	Representative graph	Pattern
EKG		Increased heart rate
Serum assay		No troponin level change
Thermometer		No temperature change
Pulse oximetry		No blood – O ₂ saturation change

Fig. 161

Sensor	Representative graph	Pattern
--------	----------------------	---------




Fig. 162


Signal	Representative graph	Pattern
EKG		Decreased heart rate
Sphygmomanometer		Decreased blood pressure
Thermometer		No temperature change
Pump infusion rate		Increased <i>propofol</i> levels

Fig. 163




Change in Variable	Representative graph	Pattern detection response
Resting value		None
Magnitude doubles		Increased signal
Duration doubles		Increased signal
Value exceeds a threshold		Alarm triggered
Slope exceeds a threshold		Increased signal

Fig. 164

Heart rate	Blood pressure	Response
normal	normal	no alert
low increase	normal	no alert
medium increase	normal	alert
low increase	low increase	alert

Fig. 165




Fig. 166




Fig. 167